Skip to content

Human Papillomavirus and Oropharynx Carcinoma

Impact of the Human Papillomavirus (HPV) Status in Carcinologic Prognosis of Oropharynx Squamous Cell Carcinoma.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00918710
Acronym
Papillophar
Enrollment
362
Registered
2009-06-11
Start date
2009-05-31
Completion date
2017-05-31
Last updated
2017-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oropharyngeal Neoplasms

Keywords

Squamous cell carcinoma of Oropharynx, Human papillomavirus., Biological prognostic markers.

Brief summary

High risk papillomavirus (HR-HPV) have an oncogenic role in Oropharyngeal squamous cell carcinomas (OP-SCC) in at least 25% of the cases and the prevalence is increasing. HPV+ might be more chemo and radio sensible with a better prognosis (disease-free survival (DFS) and overall survival (OS) as compared to HPV negative OP-SCC ; hypothesis : 2y DFS \> 20% improvement). The principal objective is to determine the impact of the status of HR-HPV in the prognosis of the OP-SCC. The principal criteria is the 2-years DFS. Secondary objective : virologic characteristics of HPV+ tumors.

Detailed description

The study has no impact on the treatment of the observed population. The clinical study include TNM status, previous story of HPV infection, smoking and alcoholic habits, treatment and outcome during 5 years. The virologic study include : HPV type, E6-E7 viral charge of HPV16, viral DNA integration in the tumoral genome, HPV16 variants, expression of HPV 16, 18, 31, 45 coding oncoproteins E6-E7 mRNA. Moreover a serologic study will be done.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Squamous cell carcinoma of Oropharynx proven histologically * All stages TNM * informed consent * No previous or simultaneous Head Neck cancer * Age \>18

Exclusion criteria

* Squamous cell carcinoma other than oropharynx * 2nd synchronous SCC localization * No consent * age \< 18

Design outcomes

Primary

MeasureTime frame
DFS at 2 years in HPV + and - tumorsat 2 years

Secondary

MeasureTime frame
Overall survivalAt 2 years
HPV statusAt the inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026